Loading...
The quartet of recent drug approvals that began with darunavir in 2006 and was followed by maraviroc and raltegravir in 2007 and then etravirine this year (AIDS Clin Care Jan 28 2008) has completely transformed the management of treatment-experienced patients. These drugs all demonstrated impressive rates of virologic suppression in the pivotal studies that led to their approvals — specifically, the POWER (darunavir), MOTIVATE (maraviroc), BENCHMRK (raltegravir), and DUET (etravirine) studies. (For detail on these studies, see AIDS Clin Care Apr 9 2007, JW Infect Dis Oct 1 2008, JW Infect Dis Jul 23 2008, and AIDS Clin Care Jul 30 2007, respectively.)
Of course, research does not always translate into practice, but, in this instance, the rea…